CD274 and non-small cell lung carcinoma: Pembrolinzumab is an ICI which is recommended as first‐line treatment for advanced NSCLC showing ≥50% expression of programmed death‐ligand 1 (PD‐L1), or treatment of patients with NSCLC whose tumors express PD‐L1 ≥ 1%.